Performance characteristics and costs of serological tests for brucellosis in a pastoralist community of northern Tanzania.
Performance characteristics and costs of serological tests for brucellosis in a pastoralist community of northern Tanzania.
复制标题
DOI：
10.1038/s41598-021-82906-w
复制
发表时间：
2021-03-09
影响因子：
4.6
通讯作者：
Mmbaga BT
中科院分区：
文献类型：
--
作者：
Lukambagire AS;Mendes ÂJ;Bodenham RF;McGiven JA;Mkenda NA;Mathew C;Rubach MP;Sakasaka P;Shayo DD;Maro VP;Shirima GM;Thomas KM;Kasanga CJ;Kazwala RR;Halliday JEB;Mmbaga BT
整个撒哈拉以南非洲地区的布鲁氏菌病控制工作因缺乏标准化检测和使用性能差的检测而受到阻碍。本研究评价了坦桑尼亚北方牧民社区人类布鲁氏菌病血清学检测的性能和成本。从218例发热住院患者中收集的血清用于评价根据国际推荐或当前使用选择的七项指标测试的性能。我们使用两种方案、四种商业凝集试验和竞争性酶联免疫吸附试验（cELISA）评价了虎红试验（RBT）。评估各指标检测的敏感性、特异性、阳性预测值、阴性预测值、约登指数、诊断准确性和每样本成本。RBT的诊断准确性估计值范围为95.9%至97.7%，商业平板检测为55.0%至72.0%，cELISA为89.4%。每个样本的成本范围为RBT 0.69 - 0.79美元，商业平板测试1.03 - 1.14美元，cELISA 2.51美元。广泛使用的商业平板测试表现不佳，成本高于RBT。这些发现为坦桑尼亚停止使用人类布鲁氏菌病商业凝集试验的公共卫生价值提供了证据。
The control of brucellosis across sub-Saharan Africa is hampered by the lack of standardized testing and the use of tests with poor performance. This study evaluated the performance and costs of serological assays for human brucellosis in a pastoralist community in northern Tanzania. Serum collected from 218 febrile hospital patients was used to evaluate the performance of seven index tests, selected based on international recommendation or current use. We evaluated the Rose Bengal test (RBT) using two protocols, four commercial agglutination tests and a competitive enzyme-linked immunosorbent assay (cELISA). The sensitivity, specificity, positive predictive value, negative predictive value, Youden’s index, diagnostic accuracy, and per-sample cost of each index test were estimated. The diagnostic accuracy estimates ranged from 95.9 to 97.7% for the RBT, 55.0 to 72.0% for the commercial plate tests, and 89.4% for the cELISA. The per-sample cost range was $0.69–$0.79 for the RBT, $1.03–$1.14 for the commercial plate tests, and $2.51 for the cELISA. The widely used commercial plate tests performed poorly and cost more than the RBT. These findings provide evidence for the public health value of discontinuing the use of commercial agglutination tests for human brucellosis in Tanzania.
登录
查看更多内容
影响因子：
3.8
作者：
Assefa LM;Crellen T;Kepha S;Kihara JH;Njenga SM;Pullan RL;Brooker SJ
通讯作者：
Brooker SJ
影响因子：
2.2
作者：
GREINER, M;SOHR, D;GOBEL, P
通讯作者：
GOBEL, P
影响因子：
2.7
作者：
Ducrotoy, Marie J.;Bardosh, Kevin L.
通讯作者：
Bardosh, Kevin L.
影响因子：
2.7
作者：
Ducrotoy, M.;Bertu, W. J.;Moriyon, I.
通讯作者：
Moriyon, I.
影响因子：
7.5
作者：
Andriopoulos, Panagiotis;Kalogerakou, Antonia;Tsironi, Maria
通讯作者：
Tsironi, Maria